ABSTRACT
PARN, poly(A)-specific ribonuclease, regulates the turnover of mRNAs and the maturation and stabilization of the hTR RNA component of telomerase. Biallelic PARN mutations were associated with Høyeraal-Hreidarsson (HH) syndrome, a rare telomere biology disorder that, because of its severity, is likely not exclusively due to hTR down-regulation. Whether PARN deficiency was affecting the expression of telomere-related genes was still unclear. Using cells from two unrelated HH individuals carrying novel PARN mutations and a human PARN knock-out (KO) cell line with inducible PARN complementation, we found that PARN deficiency affects both telomere length and stability and down-regulates the expression of TRF1, TRF2, TPP1, RAP1, and POT1 shelterin transcripts. Down-regulation of dyskerin-encoding DKC1 mRNA was also observed and found to result from p53 activation in PARN-deficient cells. We further showed that PARN deficiency compromises ribosomal RNA biogenesis in patients' fibroblasts and cells from heterozygous Parn KO mice. Homozygous Parn KO however resulted in early embryonic lethality that was not overcome by p53 KO. Our results refine our knowledge on the pleiotropic cellular consequences of PARN deficiency.
Subject(s)
Dyskeratosis Congenita/metabolism , Exoribonucleases/deficiency , Fetal Growth Retardation/metabolism , Intellectual Disability/metabolism , Microcephaly/metabolism , RNA, Ribosomal/biosynthesis , Telomere Homeostasis , Telomere/metabolism , Animals , Child, Preschool , Disease Models, Animal , Dyskeratosis Congenita/genetics , Dyskeratosis Congenita/pathology , Exoribonucleases/metabolism , Female , Fetal Growth Retardation/genetics , Fetal Growth Retardation/pathology , Humans , Intellectual Disability/genetics , Intellectual Disability/pathology , Male , Mice , Mice, Knockout , Microcephaly/genetics , Microcephaly/pathology , RNA, Ribosomal/genetics , Shelterin Complex , Telomere/genetics , Telomere/pathology , Telomere-Binding ProteinsABSTRACT
Recommendations for FFP use in neonates are based on a very limited amount of data, and not on well-designed randomized controlled trials. This retrospective study was performed to analyze our experience with FFP use in neonatal intensive care unit (NICU). From January 2006 until August 2011 a total of 80 neonates were identified as having been treated with FFP. The most common indication for FFP use was prolonged PT or aPTT, representing 32.8% of all usages of FFP. Following FFT treatment PT and aPTT normalized in 42% and 60% patients, respectively. Our results suggest that FFP were often used in acceptable indications in NICU.
